GlaxoSmithKline: Carcinoma, Non-Small-Cell Lung trials
The registry lists 55 Carcinoma, Non-Small-Cell Lung studies with GlaxoSmithKline as lead sponsor. 4 are open to participants now and 24 have results posted.
Phase 1 23Phase 2 25Phase 3 8No phase 6(a study in two phases counts in both)
Studies
Open to participants first, then studies with results posted, then the rest; newest registration first within each.
- A Study of GSK5864399 Administered Alone or in Combination With Other Anti-cancer Agents in Participants With Solid TumoursNot yet recruitingNCT07947134Phase 1/2
- Expanded Access Program of Neladalkib (NVL-655) for Patients With Advanced ALK+ NSCLC or Other ALK+ Solid TumorsAvailableNCT06834074
- Expanded Access Program of Zidesamtinib (NVL-520) for Patients With Advanced ROS1+ NSCLC or Other ROS1+ Solid TumorsAvailableNCT06797362
- Neladalkib (NVL-655) for TKI-naive Patients With Advanced ALK-Positive NSCLCRecruitingNCT06765109Phase 3
- Molecular Disease Characterization Initiative (MDCI)TerminatedNCT04772053Phase 2Results posted
- Efficacy Comparison of Cobolimab + Dostarlimab + Docetaxel to Dostarlimab + Docetaxel to Docetaxel Alone in Participants With Advanced Non-small Cell Lung Cancer Who Have Progressed on Prior Anti-PD-(L)1 Therapy and ChemotherapyActive, not recruitingNCT04655976Phase 2/3Results posted
- Efficacy Comparison of Dostarlimab Plus Chemotherapy Versus Pembrolizumab Plus Chemotherapy in Participants With Metastatic Non-squamous Non-small Cell Lung Cancer (NSCLC)TerminatedNCT04581824Phase 2Results posted
- Placebo-controlled Study Comparing Niraparib Plus Pembrolizumab Versus Placebo Plus Pembrolizumab as Maintenance Therapy in Participants With Advanced/Metastatic Non-Small Cell Lung CancerCompletedNCT04475939Phase 3Results posted
- Platform Trial of Novel Regimens Versus Standard of Care (SoC) in Participants With Non-small Cell Lung Cancer (NSCLC)CompletedNCT03739710Phase 2Results posted
- Pilot Immunotherapy Study With Letetresgene Autoleucel (Lete-cel, GSK3377794)T-cells in New York Esophageal Squamous Cell Carcinoma-1 (NY-ESO-1)/ LAGE-1a-positive Advanced Non-small Cell Lung Cancer (NSCLC) Either Alone or in Combination With PembrolizumabTerminatedNCT03709706Phase 1/2Results posted
- GSK3359609 Plus Tremelimumab for the Treatment of Advanced Solid TumorsCompletedNCT03693612Phase 1/2Results posted
- Dose Escalation and Expansion Study of FLX475 Monotherapy and in Combination With PembrolizumabCompletedNCT03674567Phase 1/2Results posted
- Study of Niraparib, TSR-022, Bevacizumab, and Platinum-Based Doublet Chemotherapy in Combination With TSR-042CompletedNCT03307785Phase 1Results posted
- An Open-label, Dose Escalation Study to Investigate the Safety, Pharmacokinetics, Pharmacodynamics and Clinical Activity of GSK3326595 in Participants With Solid Tumors and Non-Hodgkin's LymphomaCompletedNCT02783300Phase 1Results posted
- Letetresgene Autoleucel Engineered T Cells in NY-ESO -1 Positive Advanced Non-Small Cell Lung Cancer (NSCLC)CompletedNCT02588612Phase 1Results posted
- GSK3174998 Alone and With Pembrolizumab in Participants With Advanced Solid Tumors (ENGAGE-1)CompletedNCT02528357Phase 1Results posted
- A Study to Demonstrate the Benefit of a New Kind of Anti-cancer Treatment [PReferentially Expressed Antigen of MElanoma (PRAME) Immunotherapy] for Patients With Non-Small Cell Lung Cancer (NSCLC), After Removal of Their TumorCompletedNCT01853878Phase 2Results posted
- An Open-label Study of GSK1120212 Compared With Docetaxel in Stage IV KRAS-mutant Non-small Cell Lung CancerCompletedNCT01362296Phase 2Results posted
- A Study to Evaluate Pazopanib in Comparison to Pemetrexed in Maintenance Setting in Non-progressing Subjects With Metastatic Stage IVA and IVB Non-squamous Non-small Cell Lung Cancer (NSCLC) PopulationTerminatedNCT01313663Phase 2Results posted
- Study of Pazopanib and Pemetrexed in Advanced Non-small Cell Lung CancerCompletedNCT00871403Phase 2Results posted
- Expression Analysis of Specific Markers in Non-small Cell Lung Cancer or MelanomaTerminatedNCT00685750Not applicableResults posted
- Monotherapy Pazopanib in Subjects With Advanced Non-Small Cell Lung CancerTerminatedNCT00549328Phase 2Results posted
- GSK1572932A Antigen-Specific Cancer Immunotherapeutic as Adjuvant Therapy in Patients With Non-Small Cell Lung CancerTerminatedNCT00480025Phase 3Results posted
- Oral HYCAMTIN Plus Whole Brain Radiation Therapy In Treatment Of Brain Metastases Resulting From Non-Small Lung CancerCompletedNCT00390806Phase 3Results posted
- Pazopanib As Pre-Surgical Therapy In Treatment-Naive Subjects With Non-Small Cell Lung CancerCompletedNCT00367679Phase 2Results posted
- Study to Test the Efficacy of the Vaccine GSK 249553 in Treating Non-small-cell Lung Cancer After Tumour Removal by SurgeryCompletedNCT00290355Phase 2Results posted
- A Study Of Oral GW572016 In Advanced Or Metastatic Non-Small Cell Lung CancerTerminatedNCT00073008Phase 2Results posted
- Comparison of IV Topotecan/Docetaxel to Docetaxel Alone in Second-Line Stage IIIB/IV Non-Small Cell Lung CancerCompletedNCT00065182Phase 2Results posted
- A Study of Belrestotug Plus Dostarlimab Compared With Placebo Plus Pembrolizumab in Previously Untreated Participants With Programmed Death Ligand 1 (PD-L1) High Non-small-cell Lung Cancer (NSCLC)Active, not recruitingNCT06472076Phase 3
- Evaluation of Programmed Death Ligand 1 (PDL1) Response to Treatment in Extracellular Vesicles (EVs), Patient-derived Organoid (PDOs)s and Immune-marker Positron Emission Tomography (PET) Scanning in Non-small Cell Lung Cancer (NSCLC)TerminatedNCT06405230Phase 1/2
- A Platform Study of Novel Immunotherapy Combinations in Participants With Previously Untreated, Advanced/Metastatic Non-Small-Cell Lung CancerActive, not recruitingNCT05565378Phase 2
- First-Time-in-Human Study of GSK4381562 in Participants With Advanced Solid TumorsActive, not recruitingNCT05277051Phase 1
- Patient-Reported Outcome Measurement Information System (PROMIS) Physical FunctionCompletedNCT03351140
- A Study of TSR-022 in Participants With Advanced Solid Tumors (AMBER)Active, not recruitingNCT02817633Phase 1
- Study of TSR-042, an Anti-programmed Cell Death-1 Receptor (PD-1) Monoclonal Antibody, in Participants With Advanced Solid TumorsActive, not recruitingNCT02715284Phase 1
- Efficacy and Safety of Momelotinib Combined With Trametinib in Adults With Metastatic KRAS-mutated Non-Small Cell Lung Cancer (NSCLC) Who Have Failed Platinum-Based Chemotherapy Preceded by a Dose-finding Lead-in PhaseTerminatedNCT02258607Phase 1
- A Phase I/IIa Open-Label, Dose Escalation and Cohort Expansion Trial of Oral TSR-011 in Patients With Advanced Solid Tumors and LymphomasCompletedNCT02048488Phase 1/2
- A Study to Evaluate Foretinib in Subjects With Non-Small-Cell Lung CancerWithdrawnNCT02034097Phase 2
- Safety and Tolerability of Trametinib in Combination With Docetaxel in Japanese Subjects With Non-small Cell Lung CancerWithdrawnNCT01938456Phase 1
- Analysis of the Incidence of Expression of Tumor Antigens in Pathologically Proven Stage I, II and III Non-Small Cell Lung Cancer(NSCLC) in Asiatic PatientsCompletedNCT01837511
- NSCLC Burden of Illness StudyCompletedNCT01772225
- Trial of GSK1120212 and GSK1120212 in Combination With GEM in Japanese Subjects With Solid TumorsCompletedNCT01324258Phase 1
- Evaluation of a New Anti-cancer Vaccine for Patients With Non-small Cell Lung Cancer, After Tumor Removal by SurgeryTerminatedNCT01159964Phase 1
- Study of Pazopanib and Paclitaxel in Advanced Non-small Cell Lung CancerCompletedNCT00866528Phase 1
- A Phase I, Open-label, Study of Pazopanib in Combination With Gemcitabine and Gemcitabine Plus Cisplatin for Advanced Solid TumorsCompletedNCT00678977Phase 1
- A Phase I Study Of Pazopanib With Either Erlotinib Or Pemetrexed In Patients With Advanced Solid TumorsCompletedNCT00619424Phase 1
- A Study of Mapatumumab in Combination With Paclitaxel and Carboplatin in Subjects With Non-small Cell Lung CancerCompletedNCT00583830Phase 2
- A Phase II Trial of Lapatinib (TYKERB) + Pemetrexed (ALIMTA) in Advanced Non Small Cell Lung Cancer With an Initial Dose Finding PhaseCompletedNCT00528281Phase 1
- Cancer Immunotherapy GSK1572932A as Adjuvant Therapy for Patients With Tumor-antigen-positive Non-Small Cell Lung CancerTerminatedNCT00455572Phase 1
- Effects Of Nadroparin In Patients With Lung, Pancreas Or Prostate CancerCompletedNCT00312013Phase 3
- Study of TRM-1(TRAIL-R1 Monoclonal Antibody) in Subjects With Relapsed or Refractory Non-Small Cell Lung Cancer (NSCLC)CompletedNCT00092924Phase 2
- Ispinesib In Patients With Advanced Or Metastatic Non-Small Cell Lung CancerCompletedNCT00085813Phase 2
- Safety and Immunogenicity of Recombinant DNA and Adenovirus Expressing L523S Protein in Early Stage Non-Small Cell Lung CancerStatus unknownNCT00062907Phase 1
- Oral Topotecan Versus Intravenous Docetaxel In Pretreated, Advanced Non-Small Cell Lung CancerCompletedNCT00049998Phase 3
- Vinorelbine in Treating Patients With Stage IIIB or Stage IV Non-Small Cell Lung CancerCompletedNCT00005865Phase 2